Inventiva Announces Presentation of Scientific Abstract at American Diabetes Association’s 82nd Scientific Sessions

daix (France), Long Island City (New York, United States), June 3, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the development of small molecules administered orally for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other significant unmet medical needs, today announces the selection of abstract . at “The Pan-PPAR agonist lanifibranor improves nonalcoholic steatohepatitis (NASH) and glycemic control” for a poster presentation during the 82N/A Scientific Sessions of the American Diabetes Association to be held in New Orleans, United States, from June 3 to 7, 2022.

PPAR signaling is involved in disease pathways common in NASH and type 2 diabetes (T2D). This summary highlights the improvement in glycemic control and NASH markers in patients treated with lanifibranor compared to placebo. In Inventiva’s Phase IIb ‘NATIVE’ clinical trial, compared to placebo, lanifibranor showed beneficial effects on liver histology, resolution of NASH and reduction of fibrosis in patients with non-cirrhotic NASH.

Based on data from NATIVE, the authors of the abstract show that glycemic control is correlated with the severity of NASH measured by liver biopsy. In addition, improved glycemic control in patients receiving lanifibranor correlates with improved metabolic and immune markers of NASH: insulin resistance, lipid metabolism, inflammation, liver enzymes, and fatty liver, as measured by the continuous attenuation parameter (CAP).

The details of the presentation are as follows:

Date June 5, 2022
Session time: 1:00 PM – 2:00 PM (East Coast Time)
poster number: 830-P
Title of the summary: “The Pan-PPAR agonist lanifibranor improves nonalcoholic steatohepatitis (NASH) and glycemic control”
Author dr. Michael P. Cooreman, Medical Director of Inventiva

About Inventiva

Inventiva is a biopharmaceutical company specializing in the research and development of orally administered small molecules for the treatment of patients with NASH and other diseases with significant unmet medical needs. The Company has significant experience and expertise in the development of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Lanifibranor, Inventiva’s most advanced drug candidate, is currently being evaluated in the pivotal phase III clinical NATiV3 trial for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there is currently no approved treatment.

The company entered into a strategic partnership with AbbVie in the field of autoimmune diseases, which led to the discovery of the drug candidate cedirogant (ABBV-157), an orally administered RORγ inverse agonist that has shown efficacy in adult patients with moderate to severe plaque psoriasis is undermined. evaluated in a Phase IIb clinical trial conducted by AbbVie. Inventiva’s portfolio also includes odiparcil, a drug candidate for the treatment of adult patients with mucopolysaccharidosis (MPS) type VI. As part of its decision to focus its clinical efforts on the development of lanifibranor, Inventiva has discontinued its clinical efforts with odiparcil and is reviewing all available options to optimize its development. Inventiva is in the process of selecting a drug candidate in oncology as part of its program focused on the Hippo signaling pathway.

The company has a scientific team of approximately 80 people with strong expertise in biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as clinical development. Inventiva has a chemical library of approximately 240,000 molecules, approximately 60% of which are exclusive to the company, as well as its own labs and equipment.

Inventiva is listed on compartment C of the regulated market of Euronext Paris (Euronext Paris: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (symbol: IVA).



This press release contains forward-looking statements, forecasts and estimates with respect to Inventiva’s clinical studies, clinical development plans, development phase, royalty payments and Inventiva’s future activities. Some of these statements, forecasts and estimates may be identified by the use of words such as, but not limited to, “believes”, “anticipates”, “expects”, “projects”, “plans”, “seeks”, “estimates” , “can”, “will”, “continue”, “plan”, and other similar expressions. These statements do not relate to proven historical facts, but constitute projections, estimates and other forward-looking data based on management’s opinion, expectations regarding the potential commercial success and revenue potential of Inventiva’s drug candidates. These statements reflect the opinions and assumptions made as of the date they were made. They are subject to known and unknown risks and uncertainties that could cause future results, performance or events to differ materially from those indicated or implied by such statements. Actual events are difficult to predict and may depend on factors beyond Inventiva’s control. With respect to the pipeline of product candidates, there can be no assurance that the results of clinical studies will be available on time, that future clinical studies will be launched as planned, or that these candidates will receive the necessary regulatory approvals. Actual results may differ from future results described, implied or expected in such forward-looking statements due to a number of important factors, including the fact that Inventiva is a clinical-stage company with no approved products and has no history of revenue from the sale of Products. These factors include, in particular, the significant losses generated since Inventiva’s incorporation, a limited company history, the absence of income generated from the sale of Inventiva’s products, the need for additional resources to finance its operations. The future success of Inventiva also depends on the successful clinical development, receipt of regulatory approvals and subsequent commercialization of its current and future product candidates. Preclinical studies or previous clinical studies are not necessarily predictive of future results, and the results of Inventiva’s clinical studies may not support the reported benefits of Inventiva’s product candidates. Inventiva may experience significant delays in its clinical trials or Inventiva may fail to demonstrate the safety and efficacy of its products to the relevant regulatory authorities. Recruiting and retaining patients for clinical trials is a costly and time-consuming process that can be made more difficult or impossible by multiple factors beyond Inventiva’s control. Inventiva’s product candidates could cause adverse effects or have other properties that could delay or prevent regulatory approval or limit their commercial potential. The condition and results of operations could be significantly affected by the COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine, which could delay or delay the start, recruitment and completion of Inventiva’s clinical trials on schedule. Given these uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the date of this press release. Readers are therefore cautioned not to place undue reliance on these forward-looking statements.

We invite you to refer to the Universal Registration Document for the fiscal year ending December 31, 2021, filed with the Autorité des Marchés Financiers on March 11, 2022 and to the Annual Report (“Form 20-F”) for the fiscal year ending December 31. , 2021 filed with the Securities and Exchange Commission on March 11, 2022 for additional information about such factors, risks and uncertainties.

Subject to applicable regulations, Inventiva undertakes no obligation to update or revise the information contained in this press release. Inventiva can therefore not be held liable for the consequences that may arise from the use that may be made of these statements.

  • Inventiva – PR – ADA – FR – 03062022

Print friendly, PDF and email

Leave a Comment